Mel Valerie Cruz-Ordinario

Mel Valerie Cruz-Ordinario

Auto-generated profile, based on publicly available information

Mel Valerie Cruz-Ordinario

Department of Medical Oncology, St. Luke's Medical Center-Quezon City, Quezon City, Philippines

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2026 in ESMO Open
Verified
Journal Article
Open access
AWA.N.M. Wong
A.N.M. Wong
PFPaula Franco
Paula Franco
HSH.S. Sheikh
H.S. Sheikh
OPO. Pitiyarachchi
O. Pitiyarachchi
NPN. Prasongsook
N. Prasongsook
NCN. Cherny
N. Cherny
The European Society for Medical Oncology (ESMO) conducted a global survey on the availability, out-of-pocket costs (OPCs), and accessibility of cancer medicines in 2015, with an updated survey in 2023. The Asia-Pacific (APAC) region accounts for approximately half of global cancer-related deaths, yet substantial disparities persist in access to essential cancer medicines. A focused analysis of the 2023 ESMO global survey was undertaken to evaluate access trends specific to the APAC region. Data from the 2023 ESMO global survey were analysed to assess the availability, access, and OPC of cancer medicines in APAC countries, using the World Health Organization's Essential Medicines List as a benchmark. Countries included in the analysis were Australia, Taiwan (China), Japan, New Zealand, Republic of Korea, Singapore, China, Malaysia, Thailand, Bangladesh, Cambodia, India, Indonesia, Mongolia, Myanmar, Nepal, Papua New Guinea, Philippines, Vanuatu, and Vietnam. Selected case studies, including immunotherapy and oral targeted therapies, were used to explore access and regulatory approval timelines. A descriptive comparison of health technology assessment processes across APAC countries was also conducted. Availability and access to antineoplastic medicines in APAC remain limited, particularly in low- and middle-income countries. Although novel therapies are generally available, they often incur substantial OPC burdens on patients. The case studies reveal considerable delays in regulatory approval for both immunotherapy and targeted therapies across the region. Despite the introduction of innovative cancer therapies, substantial inequities in access and availability persist across APAC. Coordinated regional policies and streamlined regulatory processes may improve equitable access in the region.

7 November 2026 in The Lancet Regional Health - Southeast Asia
Verified
Journal Article
Open access
PPPankaj Kumar Panda
Pankaj Kumar Panda
PMPrashant Mathur
Prashant Mathur
SCShantanu Chowdhury
Shantanu Chowdhury
ATAaron C. Tan
Aaron C. Tan
GPGiang Hoang Pham
Giang Hoang Pham
BSBhawna Sirohi
Bhawna Sirohi


21 April 2023
Verified
Preprint
Open access
PDF file
MCMel Valerie Cruz-Ordinario
Mel Valerie Cruz-Ordinario
YKYuki Kojima
Yuki Kojima
KSKazuki Sudo
Kazuki Sudo
MIMinako Iida
Minako Iida
OSOkamoto Shinichiro
Okamoto Shinichiro
MIMarcelo Severino B. Imasa
Marcelo Severino B. Imasa
Aim: This study aimed to clarify the actual status of clinical trials and translational research activities in cancer immunology in the Asia-Pacific region, the most diverse and populous region with a large number of cancer patients. Methods: This questionnaire-based survey targeted researchers and healthcare professionals in the Asia-Pacific region. The questionnaire was sent to individuals who were involved in any collaboration with the National Cancer Center, Japan, or who belonged to the Asia-Pacific Blood and Marrow Transplantation group. Results: We received 122 responses from 20 Asia-Pacific countries and regions. Approximately 58% of the respondents were currently conducting clinical trials on cancer immunotherapy, with 25% having performed >10 phase 3 trials in the last 3 years. Half of the respondents (51.7%) belonged to institutions that conducted early phase clinical trials. In clinical trials, immune checkpoint inhibitors were used in most countries (81.8%), whereas chimeric antigen receptor T-cell (CAR-T) or T-cell receptor-modified T-cell (TCR-T) therapies were used in few countries (CAR-T, 22.7%; TCR-T, 2.3%). Importantly, 18% of respondents had referred their patients to facilities conducting suitable ongoing clinical trials in foreign countries. Some institutions provided hematopoietic stem cell transplantation (HSCT), including allogeneic HSCT (55.1%) and autologous peripheral blood stem cell transplantation (81.3%). Approximately 40% of the respondents belonged to institutions that conducted translational research on cancer immunotherapy using patient-derived samples. Conclusion: This survey revealed limited cancer immunotherapy accessibility and research activities in the Asia-Pacific region, especially for CAR-T and TCR-T therapies.